Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 132 Records) |
| Query Trace: Colorectal Neoplasms and UGT1A1[original query] |
|---|
| Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. Tumori 2018 12 106 (2): 87-94. Paulík Adam, Nekvindová Jana, Filip Stanisl |
| Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. Translational oncology 2019 Mar 12 (3): 502-512. Ma Cheng-Jen, Huang Ching-Wen, Chang Tsung-Kun, Tsai Hsiang-Lin, Su Wei-Chih, Yeh Yung-Sung, Chen Po-Jung, Wang Jaw-Yu |
| Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. British journal of cancer 2019 Jan 120 (2): 190-195. Páez David, Tobeña María, Fernández-Plana Julen, Sebio Ana, Virgili Anna C, Cirera Lluís, Barnadas Agustí, Riera Pau, Sullivan Ivana, Salazar Julia |
| A study of the association between UGT1A1*28 variant allele of UGT1A1 gene and colonic phenotype of sporadic colorectal cancer. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2019 04 51 (4): 579-583. Anon Benjamin, Perray Clémence, Regnault David, Caulet Morgane, Orain Isabelle, Godart Bruno, Pages Jean-Christophe, Tallet Anne, Ouaissi Mehdi, Guyetant Serge, Barin-le Guellec Chantal, Lecomte Thier |
| A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer. Journal of clinical pharmacy and therapeutics 2019 8 44 (6): 946-951. Yamazaki Kaori, Ariyoshi Noritaka, Miyauchi Hideaki, Ohira Gaku, Kaneya Noriko, Yamamoto Kohei, Arai Kenichi, Yamazaki Shingo, Matsubara Hisahiro, Suzuki Takaaki, Ishii Itsu |
| Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Therapeutic advances in medical oncology 2019 6 11 1758835919846421. Bruera Gemma, Massacese Silvia, Pepe Francesco, Malapelle Umberto, Dal Mas Antonella, Ciacco Eugenio, Calvisi Giuseppe, Troncone Giancarlo, Simmaco Maurizio, Ricevuto Enri |
| Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. Trials 2019 Dec 20 (1): 751. Ma Cheng-Jen, Chang Tsung-Kun, Tsai Hsiang-Lin, Su Wei-Chih, Huang Ching-Wen, Yeh Yung-Sung, Chang Yu-Tang, Wang Jaw-Yu |
| Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics 2019 1 20 (4): 241-249. Wei XiaoXia, Cai JiaQin, Sun Hong, Li Na, Xu Chenxia, Zhang Guifeng, Sui Yuxia, Zhuang Jie, Zheng B |
| Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. BMC medicine 2020 Sep 18 (1): 229. Seyed Khoei Nazlisadat, Jenab Mazda, Murphy Neil, Banbury Barbara L, Carreras-Torres Robert, Viallon Vivian, Kühn Tilman, Bueno-de-Mesquita Bas, Aleksandrova Krasimira, Cross Amanda J, Weiderpass Elisabete, Stepien Magdalena, Bulmer Andrew, Tjønneland Anne, Boutron-Ruault Marie-Christine, Severi Gianluca, Carbonnel Franck, Katzke Verena, Boeing Heiner, Bergmann Manuela M, Trichopoulou Antonia, Karakatsani Anna, Martimianaki Georgia, Palli Domenico, Tagliabue Giovanna, Panico Salvatore, Tumino Rosario, Sacerdote Carlotta, Skeie Guri, Merino Susana, Bonet Catalina, Rodríguez-Barranco Miguel, Gil Leire, Chirlaque Maria-Dolores, Ardanaz Eva, Myte Robin, Hultdin Johan, Perez-Cornago Aurora, Aune Dagfinn, Tsilidis Konstantinos K, Albanes Demetrius, Baron John A, Berndt Sonja I, Bézieau Stéphane, Brenner Hermann, Campbell Peter T, Casey Graham, Chan Andrew T, Chang-Claude Jenny, Chanock Stephen J, Cotterchio Michelle, Gallinger Steven, Gruber Stephen B, Haile Robert W, Hampe Jochen, Hoffmeister Michael, Hopper John L, Hsu Li, Huyghe Jeroen R, Jenkins Mark A, Joshi Amit D, Kampman Ellen, Larsson Susanna C, Le Marchand Loic, Li Christopher I, Li Li, Lindblom Annika, Lindor Noralane M, Martín Vicente, Moreno Victor, Newcomb Polly A, Offit Kenneth, Ogino Shuji, Parfrey Patrick S, Pharoah Paul D P, Rennert Gad, Sakoda Lori C, Schafmayer Clemens, Schmit Stephanie L, Schoen Robert E, Slattery Martha L, Thibodeau Stephen N, Ulrich Cornelia M, van Duijnhoven Franzel J B, Weigl Korbinian, Weinstein Stephanie J, White Emily, Wolk Alicja, Woods Michael O, Wu Anna H, Zhang Xuehong, Ferrari Pietro, Anton Gabriele, Peters Annette, Peters Ulrike, Gunter Marc J, Wagner Karl-Heinz, Freisling Hei |
| Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis. Bioscience reports 2020 Sep . Zhu Xiaoyun, Ma Ruchao, Ma Xin, Yang Ga |
| Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy. Frontiers in oncology 2020 8 10 1155. Bruera Gemma, D'Andrilli Antonio, Simmaco Maurizio, Guadagni Stefano, Rendina Erino Angelo, Ricevuto Enri |
| Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). European journal of cancer (Oxford, England : 1990) 2020 Aug 138 19-29. Tsai Hsiang-Lin, Huang Ching-Wen, Lin Yi-Wen, Wang Jui-Ho, Wu Chang-Chieh, Sung Yung-Chuan, Chen Tzu-Liang, Wang Hwei-Ming, Tang Hsiu-Chin, Chen Joe-Bin, Ke Tao-Wei, Tsai Chang-Sung, Huang Hsuan-Yuan, Wang Jaw-Yu |
| Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
| ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in pharmacology 2020 7 11 973. Riera Pau, Artigas-Baleri Alícia, Salazar Juliana, Sebio Ana, Virgili Anna C, Arranz María Jesús, Páez Dav |
| Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang. BMC gastroenterology 2020 Apr 20 (1): 96. Chen Shaojun, Hua Li, Feng Chengjun, Mo Qia, Wei Mengzhuan, Shen Yongqi, Lin Zhan, Li Guisheng, Xu Junyi, Guo Chengxian, Huang Haix |
| UGT1A1 regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa. Pharmacogenomics 2021 9 22 (15): 963-972. Mathew Jenny Mary, Mpangase Phelelani Thokozani, Sengupta Dhriti, Kwenda Stanford, Mavri-Damelin Demetra, Ramsay Michè |
| Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. Cancer science 2021 7 112 (11): 4669-4678. Iwasa Satoru, Muro Kei, Morita Satoshi, Park Young Suk, Nakamura Masato, Kotaka Masahito, Nishina Tomohiro, Matsuoka Hiroshi, Ahn Joong Bae, Lee Keun-Wook, Hong Yong Sang, Han Sae Won, Cho Sang-Hee, Zhang Dong-Sheng, Fang Wei-Jia, Bai Li, Yuan Xiang-Lin, Yuan Ying, Yamada Yasuhide, Sakamoto Junichi, Kim Tae W |
| Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature. Innovations in pharmacy 2021 5 11 (3): . Argevani Lia, Hughes Caren, Schuh Michael |
| UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI. Journal of oncology 2021 3 2021 6686517. Hsieh Yi-Chien, Chang Tsung-Kun, Su Wei-Chih, Huang Ching-Wen, Tsai Hsiang-Lin, Chen Yen-Cheng, Li Ching-Chun, Chen Po-Jung, Yin Tzu-Chieh, Ma Cheng-Jen, Wang Jaw-Yu |
| DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology 2021 Nov . Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim |
| Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only. Cancer management and research 2022 5 14 1541-1549. Li Ching-Chun, Chang Tsung-Kun, Chen Yen-Cheng, Tsai Hsiang-Lin, Huang Ching-Wen, Su Wei-Chih, Ma Cheng-Jen, Yin Tzu-Chieh, Chen Po-Jung, Wang Jaw-Yu |
| Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2022 3 25 (3): 137-146. Li Qian, Sun Tao, Zhang Hua, Liu Wei, Xiao Yu, Sun Hongqi, Yin Wencheng, Yao Yanhong, Gu Yangchun, Liu Yan'e, Yi Fumei, Wang Qiqi, Yu Jinyu, Cao Baoshan, Liang |
| Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy. Oncology research 2022 Feb . Tsai Hsiang-Lin, Chen Yen-Cheng, Yin Tzu-Chieh, Su Wei-Chih, Chen Po-Jung, Chang Tsung-Kun, Li Ching-Chun, Huang Ching-Wen, Wang Jaw-Yu |
| Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine 2022 10 . Kanesada Kou, Tsunedomi Ryouichi, Hazama Shoichi, Ogihara Hiroyuki, Hamamoto Yoshihiko, Shindo Yoshitaro, Matsui Hiroto, Tokumitsu Yukio, Yoshida Shin, Iida Michihisa, Suzuki Nobuaki, Takeda Shigeru, Ioka Tatsuya, Nagano Hiroa |
| Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2022 Jul 46 (4): 224-233. Miarons Marta, Riera Pau, García-Gil Sara, Gutiérrez-Nicolás Fernan |
| Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
| A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
| Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAF-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study. Medicina (Kaunas, Lithuania) 2023 12 59 (12): . Hsiang-Lin Tsai, Ching-Wen Huang, Yen-Cheng Chen, Wei-Chih Su, Tsung-Kun Chang, Po-Jung Chen, Ching-Chun Li, Yu-Tang Chang, Jaw-Yuan Wa |
| A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? Cancer chemotherapy and pharmacology 2023 11 . Angeline Ginzac, Emilie Thivat, Caroline Petorin, Damien Richard, Pauline Herviou, Ioana Molnar, Hervé Devaud, Isabelle Creveaux, Florent Ferrer, Nicolas Authier, Marine Jary, Denis Pezet, Xavier Duran |
| Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients. Pharmacogenomics 2024 8 1-10. Cuc Thi Thu Nguyen, Nguyen Thi Minh Thuy, Phung Thanh Huo |
- Page last reviewed:Feb 1, 2024
- Content source: